Nucleic Acid Therapeutics Market Forecast with Size and Share Analysis 2026 to 2035
What is Nucleic Acid Therapeutics Market Size?
Nucleic Acid Therapeutics Market Size is valued at USD 5.69 billion in 2025 and is predicted to reach USD 15.43 billion by the year 2035 at a 10.9% CAGR during the forecast period for 2026 to 2035.
Nucleic Acid Therapeutics Market Size, Share & Trends Analysis Report By Technology (RNA targeted therapeutics, Gene Therapies, Epigenetic and microRNA modulating therapies, Genome editing therapies, Others), By Application (Autoimmune Disorders, Genetic Disorders, Infectious Diseases, Cancer, Others), By End User (Hospitals & Clinics, Academic & Research Institutes, Others) By Region, And By Segment Forecasts, 2026 to 2035.
Nucleic Acid Therapeutics Market Key Takeaways:
|
Nucleic acid therapeutics stands for a group of medicinal interventions that prevent illness by means of nucleic acids. Cutting-edge and focused therapies for a broad spectrum of hereditary and chronic diseases are now available through gene-targeting therapies. These therapies can fix mutations, regulate gene expression, and silence dangerous genes. Rising rates of chronic diseases and genetic conditions have prompted an upsurge of studies into ways to improve healthcare systems around the world, which bodes well for the sector. Additionally, the nucleic acid therapeutics business is being propelled forward by rising demand for pharmaceuticals and healthcare services, as well as new developments in biological goods and DNA therapies. However, strict rules regarding nucleic acid therapeutics are anticipated to impede the expansion of this industry. The ongoing development of novel and improved nucleic acid therapeutics is propelling market expansion.
However, due to the high treatment costs, stringent regulatory constraints, and a general lack of knowledge of nucleic acid treatments among both patients and healthcare professionals, the nucleic acid therapeutics industry is expected to slow down market growth. The rapid advancement of research and development, the increased focus on the efficacy of mRNA vaccines, and the surge in investment and interest in nucleic acid-based treatments for infectious diseases were all beneficial effects of the COVID-19 pandemic for the nucleic acid therapeutics business. Furthermore, the demand for nucleic acid therapeutics is expected to rise due to innovative treatments receiving substantial funding from pharmaceutical firms and governments.
Competitive Landscape
Some Major Key Players In The Nucleic Acid Therapeutics Market:
- Novartis
- Moderna Inc
- BioNTech
- Arrowhead Pharmaceuticals
- Merck
- Thermo Fischer Scientific
- Sanofi
- Alnylam Pharmaceuticals
- Sarepta Therapeutics
- Qiagen
- Imugene
- Copernicus Therapeutics Inc.
- Protagonist Therapeutics
- Arbutus Biopharma
- Agilent Technologies
- Silence Therapeutics (UK),
- Astellas Pharma Inc. (Japan),
- CureVac SE (Germany),
- Sirnaomics (US),
- Arcturus Therapeutics Inc. (US)
- Other Market Players
Market Segmentation:
The nucleic acid therapeutics market is segmented based on technology, application, and end-user. By technology, the market is segmented into RNA-targeted therapeutics, gene therapies, epigenetic and microRNA-modulating therapies, genome editing therapies, and others. By application, the market is segmented into autoimmune disorders, genetic disorders, infectious diseases, cancer, and others. As per the end-user segment, the market is categorized into hospitals and clinics, academic & research institutes, and others.
Based On The Technology, The RNA Targeted Therapeutics Nucleic Acid Therapeutics Segment Is Accounted As A Major Contributor To The Nucleic Acid Therapeutics Market.
The RNA targeted therapeutics nucleic acid therapeutics category is expected to report a large global market share in 2023 due to its precision in targeting and modulating gene expression, notable progress in RNA technology, a surge in financing for RNA-based research, and the effective creation and authorization of RNA-based therapeutics for a range of illnesses, including gene diseases and viral infections.
Hospitals & Clinics Segment To Witness A Rapid Growth.
The hospitals & clinics market is expected to grow rapidly in the nucleic acid therapeutics market because of the improved healthcare infrastructure, the ability of these facilities to deliver specialized care and efficiently administer complex medications, the increasing frequency of genetic and chronic diseases, and the increasing use of modern genetic treatments, which is growing the hospital & clinics segment growth.
In The Region, The North American Nucleic Acid Therapeutics Market Holds A Significant Revenue Share.
The North American nucleic acid therapeutics market is estimated to register the maximum market share in revenue in the near future due to its state-of-the-art healthcare system, innovative treatments being readily available, and major expenditures on R&D by the pharmaceutical industry. The use of nucleic acid therapeutics is further encouraged by an increase in patient and healthcare provider understanding and comfort with these treatments. In addition, the Asia-Pacific region is expected to grow quickly in the global nucleic acid therapeutics market because of favourable government programs, a surge in investments in biotechnology, an uptick in genetic abnormalities, and a general increase in knowledge about cutting-edge medical therapies, which is growing the market demand in this area.
Recent Developments:
- In April 2024, Arrowhead Pharmaceuticals, Inc. announced the dosing of its investigational RNA interference (RNAi) therapeutic, ARO-CFB, in a Phase 1/2a clinical trial. The trial included up to sixty-six healthy volunteers and patients with complement-mediated kidney disease.
- In Aug 2022, Merck and Orna Therapeutics entered into a collaboration agreement to jointly explore, create, and market various initiatives, such as vaccines and treatments, in the fields of infectious disease and oncology.
Nucleic Acid Therapeutics Market Report Scope
| Report Attribute | Specifications |
| Market Size Value In 2025 | USD 5.69 Bn |
| Revenue Forecast In 2035 | USD 15.43 Bn |
| Growth Rate CAGR | CAGR of 10.9% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2024 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Technology, Application, And End-User |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
| Competitive Landscape | Novartis, Moderna Inc, BioNTech, Arrowhead Pharmaceuticals, Merck, Thermo Fischer Scientific, Sanofi, Alnylam Pharmaceuticals, Sarepta Therapeutics, Qiagen, Imugene, and Copernicus Therapeutics Inc. and Other Market Players |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of Nucleic Acid Therapeutics Market-
Nucleic Acid Therapeutics Market By Technology-
- RNA Targeted Therapeutics
- Gene Therapies
- Epigenetic and MicroRNA Modulating Therapies
- Genome Editing Therapies
- Others
Nucleic Acid Therapeutics Market By Applications-
- Autoimmune Disorders
- Genetic Disorders
- Infectious Diseases
- Cancer
- Others
Nucleic Acid Therapeutics Market By End-User-
- Hospitals & Clinics
- Academic & Research Institutes
- Others
Nucleic Acid Therapeutics Market By Region-
North America-
- The US
- Canada
- Mexico
Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
Latin America-
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa-
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Nucleic Acid Therapeutics Market Size is valued at USD 5.69 billion in 2025 and is predicted to reach USD 15.43 billion by the year 2035
Nucleic Acid Therapeutics Market is predicted to develop at a 10.9% CAGR during the forecast period for 2026 to 2035.
Sanofi, Alnylam Pharmaceuticals, Sarepta Therapeutics, Qiagen, Imugene, and Copernicus Therapeutics Inc. and Other Market Players